Kyverna Therapeutics (NASDAQ:KYTX) Price Target Cut to $6.00 by Analysts at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX - Free Report) had its price objective trimmed by HC Wainwright from $7.00 to $6.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

KYTX has been the subject of a number of other research reports. Wells Fargo & Company lowered their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, November 15th. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a "strong-buy" rating in a report on Wednesday, October 9th. UBS Group started coverage on shares of Kyverna Therapeutics in a report on Thursday, October 10th. They set a "buy" rating and a $13.00 price target for the company. Rodman & Renshaw assumed coverage on shares of Kyverna Therapeutics in a report on Wednesday, October 9th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kyverna Therapeutics has a consensus rating of "Buy" and an average price target of $25.71.

Kyverna Therapeutics Stock Up 1.0 %

NASDAQ:KYTX traded up $0.04 during midday trading on Wednesday, hitting $4.12. The company had a trading volume of 264,093 shares, compared to its average volume of 456,309. The stock's fifty day moving average price is $5.34 and its 200-day moving average price is $8.26. Kyverna Therapeutics has a 52-week low of $3.94 and a 52-week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. As a group, research analysts anticipate that Kyverna Therapeutics will post -3.31 EPS for the current fiscal year.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYTX. FMR LLC bought a new position in shares of Kyverna Therapeutics in the 3rd quarter valued at about $33,000. DekaBank Deutsche Girozentrale bought a new stake in Kyverna Therapeutics in the first quarter worth $181,000. Teachers Retirement System of The State of Kentucky increased its position in Kyverna Therapeutics by 69.7% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company's stock valued at $161,000 after acquiring an additional 8,796 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Kyverna Therapeutics by 32.6% in the second quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company's stock valued at $283,000 after acquiring an additional 9,300 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Kyverna Therapeutics by 55.8% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company's stock worth $196,000 after acquiring an additional 9,385 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.